Leucine Rich Repeat Serine/Threonine Protein Kinase 2 – Drugs In Development, 2021

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 – Drugs In Development, 2021, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) – Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 10 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinson's Disease, Crohn's Disease (Regional Enteritis), Glioblastoma Multiforme (GBM), Ocular Hypertension, Open-Angle Glaucoma, Pancreatic Cancer, Pulmonary Hypertension and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)

– The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

E-scape Bio Inc

Guangzhou DM Intelligence Ltd

H. Lundbeck AS

ICB International Inc

Imago Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Neuron23 Inc

Oncodesign SA

Shape Therapeutics Inc

Voronoi Group

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Overview

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Companies Involved in Therapeutics Development

Arrien Pharmaceuticals LLC

D. Western Therapeutics Institute Inc

Denali Therapeutics Inc

E-scape Bio Inc

Guangzhou DM Intelligence Ltd

H. Lundbeck AS

ICB International Inc

Imago Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Lead Discovery Center GmbH

Merck & Co Inc

Neuron23 Inc

Oncodesign SA

Shape Therapeutics Inc

Voronoi Group

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Drug Profiles

Antibody 1 to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-1104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNL-975 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ESB-5070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-7915 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-1337 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ION-859 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ODS-2005294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06447475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK-2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LRRK2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VRN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Dormant Products

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC

2.7.11.1) - Product Development Milestones

Featured News & Press Releases

May 01, 2021: Phase 1b studies of its LRRK2 inhibitor, BIIB122/DNL151, supporting late-stage development plans in Parkinson’s Disease

Aug 06, 2020: Biogen and Denali to collaborate on LRRK2 program for Parkinson’s Disease and certain tv platform-enabled programs for neurodegenerative diseases

Aug 06, 2020: Denali Therapeutics announces decision to advance DNL151 into late stage clinical studies in Parkinson’s Patients

Feb 17, 2020: Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

Sep 05, 2019: Denali begins dosing Parkinson’s patients in Phase Ib trial

Sep 04, 2019: GeoVax announces publication of Lassa Fever Vaccine study results

Sep 04, 2019: BioXcel Therapeutics receives FDA Orphan Drug Designation for BXCL701 for the treatment of Acute Myeloid Leukemia (AML)

Dec 10, 2018: Denali Therapeutics announces first patient dosed in phase 1b study of DNL201 for parkinson's disease

Aug 01, 2018: Denali Therapeutics announces positive clinical results from LRRK2 inhibitor program for parkinsons disease

Apr 05, 2018: Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma

Dec 20, 2017: Denali Therapeutics Provides Update on DNL151

Dec 20, 2017: Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson's Disease

May 23, 2017: Origenis Announces Patent Grants for Lead Small Molecule LRRK2 Inhibitors for Treatment of Neurodegenerative and Inflammatory Diseases

May 30, 2016: Oncodesign is granted new patent protecting key molecules generated from its Nanocyclix technology platform for next generation kinase inhibitors

Oct 21, 2015: Oncodesign Presents Novel LRRK2 Inhibitor Jointly Discovered with Ipsen at the 2015 Neurosciences Meeting in Chicago

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Arrien Pharmaceuticals LLC, 2021

Pipeline by D. Western Therapeutics Institute Inc, 2021

Pipeline by Denali Therapeutics Inc, 2021

Pipeline by E-scape Bio Inc, 2021

Pipeline by Guangzhou DM Intelligence Ltd, 2021

Pipeline by H. Lundbeck AS, 2021

Pipeline by ICB International Inc, 2021

Pipeline by Imago Pharmaceuticals Inc, 2021

Pipeline by Ionis Pharmaceuticals Inc, 2021

Pipeline by Lead Discovery Center GmbH, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Neuron23 Inc, 2021

Pipeline by Oncodesign SA, 2021

Pipeline by Shape Therapeutics Inc, 2021

Pipeline by Voronoi Group, 2021

Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports